Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Chubb
Baxter
Citi
Merck
Covington
Argus Health
UBS
Cantor Fitzgerald
Federal Trade Commission
Farmers Insurance

Generated: October 22, 2017

DrugPatentWatch Database Preview

Details for Patent: ► Subscribe

« Back to Dashboard

Details for Patent: ► Subscribe

Title: Indole-,benzofuran-,and benzothiophene-containing lipoxygenase-inhibiting compounds
Abstract:Pro-drugs of potent 5-lipoxygenase inhibiting compounds comprise compounds of the formula ##STR1## in which A is an alkylene or alkenylene group, X is oxygen, sulfur, sulfoxyl, or substituted nitrogen, and Y is a group which includes substituted or unsubstituted carbocyclic or substituted or unsubstituted heterocyclic aryl. R.sup.1 is an alkyl, alkenyl, amino, alkylamino, dialkylamino, or hydroxyamino group or an amine group bearing a metabolically cleavable leaving group. M is hydrogen, a pharmaceutically acceptable cation or a metabolically cleavable leaving group, with the proviso that either M or R.sup.1 must bear a metabolically cleavable leaving group.
Inventor(s): Brooks; Dee W. (Libertyville, IL), Summers; James B. (Libertyville, IL)
Assignee: Abbott Laboratories (Abbott Park, IL)
Filing Date:Jan 21, 1992
Application Number:07/823,411
Claims:1. A compound selected from the group consisting of

N-ethoxycarbonyloxy-N-[1-(benzo[b]thien-2-yl)ethyl]urea;

N-methoxycarbonyloxy-N-[1-(benzo[b]thien-2-yl)ethyl]urea;

N-tert-butoxycarbonyloxy-N-[1-(benzo[b]thien-2-yl)ethyl]urea;

N-thioethylcarbonyloxy-N-[1-(benzo[b]thien-2-yl)ethyl]urea;

N-glutaryloxy-N-[1-(benzo[b]thien-2-yl)ethyl]urea;

N-succinyloxy-N-[1-(benzo[b]thien-2-yl)ethyl]urea;

N'-acetyl-N-hydroxy-N-[1-(benzo[b]thien-2-yl)ethyl]urea; and

N'-carbamoyl-N-hydroxy-N-[1-(benzo[b]thien-2-yl)ethyl]urea.

2. A pharmaceutical composition for inhibiting lipoxygenase enzymes comprising a therapeutically effective amount of a compound as defined by claim 1 in combination with a pharmaceutically acceptable carrier.

3. A method of inhibiting lipoxygenase enzymes in a host mammal in need of such treatment comprising administering to such a mammal a therapeutically effective amount of a compound as defined by claim 1.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Citi
Fuji
Daiichi Sankyo
McKinsey
Covington
Mallinckrodt
Fish and Richardson
Johnson and Johnson
Cipla
Farmers Insurance

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot